Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dimerix Limited ( (AU:DXB) ) just unveiled an update.
Dimerix has appointed seasoned finance executive Mike Tonroe as Chief Financial Officer and Company Secretary, effective 29 January 2026, in a newly created in-house role aimed at supporting the company’s anticipated growth. Tonroe brings more than three decades of international finance and governance experience across ASX and NASDAQ-listed life sciences companies, including prior CFO and Company Secretary roles at Imugene, Opthea, Genetic Technologies and the Australian Synchrotron, with a strong track record in capital raisings, M&A and strengthening financial controls and governance. The move marks a transition from outsourced finance services to an internal leadership structure, underscoring Dimerix’s maturation as it advances its Phase 3 kidney disease asset DMX-200 and positions itself for expanded capital markets activity and strategic execution.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is an ASX-listed, clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases, particularly kidney disorders such as Focal Segmental Glomerulosclerosis (FSGS). Its lead Phase 3 product candidate, DMX-200, a CCR2 antagonist used alongside standard-of-care AT1R blockers, was discovered using the company’s proprietary Receptor-HIT assay platform, which is designed to rapidly identify new drug opportunities by analysing receptor interactions.
Average Trading Volume: 1,187,751
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$321.2M
For an in-depth examination of DXB stock, go to TipRanks’ Overview page.